Pharmacologic management of acute attacks of migraine and prevention of migraine headache

Annals of Internal Medicine

Volumn 137, Issue 10, 2002, Pages 840-849

  Snow, Vincenza ^a   Weiss, Kevin ^a   Wall, Eric M ^a   Mottur Pilson, Christel ^a  

^a AMERICAN COLLEGE OF PHYSICIANS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; AMITRIPTYLINE; ANTIEMETIC AGENT; BUTORPHANOL; CAFFEINE; CYPROHEPTADINE; DIHYDROERGOTAMINE; ERGOTAMINE; ERGOTAMINE DERIVATIVE; FLUNARIZINE; IBUPROFEN; LISURIDE; METHYSERGIDE; NAPROXEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PIZOTIFEN; PROCHLORPERAZINE; PROPRANOLOL; RIZATRIPTAN; SEROTONIN AGONIST; SUMATRIPTAN; TIMOLOL; TOLFENAMIC ACID; UNINDEXED DRUG; VALPROATE SEMISODIUM; ZOLMITRIPTAN;

ABDOMINAL PAIN; BLEEDING; BODY WEIGHT DISORDER; CHEMOPROPHYLAXIS; DEPRESSION; DIAGNOSTIC APPROACH ROUTE; DISEASE CLASSIFICATION; DOSE RESPONSE; DROWSINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEADACHE; HUMAN; INSOMNIA; LEG PAIN; MIGRAINE; NAUSEA; NEURAL TUBE DEFECT; PATIENT EDUCATION; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; REVIEW; SEDATION; TERATOGENICITY; THORAX DISEASE; TREMOR; VERTIGO; WEIGHT GAIN;

EID: 0037137173     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-137-10-200211190-00014     Document Type: Review

References (121)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001;41:646-57. [PMID: 11554952]
2. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache. 2001;41:638-45. [PMID: 11554951]
3. Matchar DB, Young WB, Rosenberg JH, Pietrzak MP, Silberstein SD, Lipton RB, et al. Evidence-Based Guidelines for Migraine Headache in the Primary Care Setting: Pharmacological Management of Acute Attacks. 2000. Accessed at www.aan.com/professionals/practice/guidelines.cfm.
4. Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM. Evidence-Based Guidelines for Migraine Headache in the Primary Care Setting: Pharmacological Management for Prevention of Migraine. 2000. Accessed at www.aan.com/professionals/practice/guidelines.cfm.
5. McCrory DC, Matchar DB, Gray RN, Rosenberg JH, Silberstein SD. Evidence-Based Guidelines for Migraine Headache: Overview of Program Description and Methodology. 2000. Accessed at www.aan.com/professionals/practice/guidelines.cfm.
6. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia. 1988;8 Suppl 7:1-96. [PMID: 3048700]
7. Silberstein SD, Lipton RB, Goadsby PJ. Classification and diagnosis of headache. In: Silberstein SD, Lipton RB, Goadsby PJ, eds. Headache in Clinical Practice. Oxford, UK: Isis Medical Media; 1998:11-8.
8. Hakkarainen H, Vapaatalo H, Gothoni G, Parantainen J. Tolfenamic acid is as effective as ergotamine during migraine attacks. Lancet. 1979;2:326-8. [PMID: 89390]
9. Boureau F, Joubert JM, Lasserre V, Prum B, Delecoeuillerie G. Double-blind comparison of an acetaminophen 400 mg-codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia. 1994;14:156-61. [PMID: 8062355]
10. Tfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: A double-blind study. Cephalalgia. 1984;4:107-11. [PMID: 6375873]
11. Havanka-Kanniainen H. Treatment of acute migraine attack: Ibuprofen and placebo compared. Headache. 1989;29:507-9. [PMID: 2676908]
12. Kloster R, Nestvold K, Vilming ST. A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia. 1992;12:169-71; discussion 128. [PMID: 1623513]
13. Sargent JD, Baumel B, Peters K, Diamond S, Saper JR, Eisner LS, et al. Aborting a migraine attack: Naproxen sodium v ergotamine plus caffeine. Headache. 1988;28:263-6. [PMID: 3139584]
14. Johnson ES, Ratcliffe DM, Wilkinson M. Naproxen sodium in the treatment of migraine. Cephalalgia. 1985;5:5-10. [PMID: 3886154]
15. Tokola RA, Kangasniemi P, Neuvonen PJ, Tokola O. Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks. Cephalalgia. 1984;4:253-63. [PMID: 6394143]
16. Lipton RB, Stewart WF, Ryan RE Jr, Saper J, Silberstein S, Sheftell F. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: Three double-blind, randomized, placebo-controlled trials. Arch Neurol. 1998;55:210-7. [PMID: 9482363]
17. Diamond S. Treatment of migraine with isometheptene, acetaminophen, and dichloralphenazone combination: A double-blind, crossover trial. Headache. 1976;15:282-7. [PMID: 1107267]
18. Klassen A, Elkind A, Asgharnejad M, Webster C, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group. Headache. 1997;37:640-5. [PMID: 9439085]
19. Mathew NT, Asgharnejad M, Peykamian M, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group. Neurology. 1997;49:1485-90. [PMID: 9409334]
20. Cutler NR, Claghorn J, Sramek JJ, Block G, Panebianco D, Cheng H, et al. Pilot study of MK-462 in migraine. Cephalalgia. 1996;16:113-6. [PMID: 8665577]
21. Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD. Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group. Arch Neurol. 1996;53:1132-7. [PMID: 8912486]
22. Gijsman H, Kramer MS, Sargent J, Tuchman M, Matzura-Wolfe D, Polis A, et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia. 1997;17:647-51. [PMID: 9350384]
23. Teall J, Tuchman M, Cutler N, Gross M, Willoughby E, Smith B, et al. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. Headache. 1998;38:281-7. [PMID: 9595867]
24. Cutler N, Mushet GR, Davis R, Clements B, Whitcher L. Oral sumatriptan for the acute treatment of migraine: Evaluation of three dosage strengths. Neurology. 1995;45:S5-9. [PMID: 7644082]
25. Myllylä VV, Havanka H, Herrala L, Kangasniemi P, Rautakorpi I, Turkka J, et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: Comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache. 1998;38:201-7. [PMID: 9563211]
26. Nappi G, Sicuteri F, Byrne M, Roncolato M, Zerbini O. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol. 1994;241:138-44. [PMID: 8164015]
27. Sumatriptan - An oral dose-defining study. The Oral Sumatriptan Dose-Defining Study Group. Eur Neurol. 1991;31:300-5. [PMID: 1653137]
28. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. The Oral Sumatriptan International Multiple-Dose Study Group. Eur Neurol. 1991;31:306-13. [PMID: 1653138]
29. Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan. Headache. 1998;38:184-90. [PMID: 9563208]
30. Pini LA, Sternieri E, Fabbri L, Zerbini O, Bamfi F. High efficacy and low frequency of headache recurrence after oral sumatriptan. The Oral Sumatriptan Italian Study Group. J Int Med Res. 1995;23:96-105. [PMID: 7601299]
31. Sargent J, Kirchner JR, Davis R, Kirkhart B. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: Results of a multicenter study. Neurology. 1995;45:S10-4. [PMID: 7644079]
32. Rapoport AM, Ramadan NM, Adelman JU, Mathew NT, Elkind AH, Kudrow DB, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology. 1997;49:1210-8. [PMID: 9371896]
33. Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology. 1997;49:1219-25. [PMID: 9371897]
34. Visser WH, Klein KB, Cox RC, Jones D, Ferrari MD. 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: A double-blind, placebo-controlled, dose-range finding study. Neurology. 1996;46:522-6. [PMID: 8614525]
35. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H Jr. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991;265:2831-5. [PMID: 1851894]
36. Mathew NT, Dexter J, Couch J, Flamenbaum W, Goldstein J, Rapoport A, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49:1271-6. [PMID: 1333181]
37. Russell MB, Holm-Thomsen OE, Rishøj Nielsen M, Cleal A, Pilgrim AJ, Olesen J. A randomized double-blind placebo-controlled crossover study of subcutaneous sumatriptan in general practice. Cephalalgia. 1994;14:291-6. [PMID: 7954759]
38. Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N Engl J Med. 1991;325:316-21. [PMID: 1647495]
39. A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group. Eur Neurol. 1991;31:332-8. [PMID: 1653141]
40. Salonen R, Ashford E, Dahlöf C, Dawson R, Gilhus NE, Lüben V, et al. Intranasal sumatriptan for the acute treatment of migraine. International Intranasal Sumatriptan Study Group. J Neurol. 1994;241:463-9. [PMID: 7964913]
41. Ryan R, Elkind A, Baker CC, Mullican W, DeBussey S, Asgharnejad M. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies. Neurology. 1997;49:1225-30. [PMID: 9371898]
42. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Dihydroergotamine Nasal Spray Multicenter Investigators. Headache. 1995;35:177-84. [PMID: 7775172]
43. Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group. Arch Neurol. 1996;53:1285-91. [PMID: 8970458]
44. Rohr J, Dufresne JJ. Dihydroergotamine nasal spray for the treatment of migraine attacks: A comparative double-blind crossover study with placebo. Cephalalgia. 1985;5(Suppl 3):142-3.
45. Tulunay FC, Karan O, Aydin N, Culcuoglu A, Guvener A. Dihydroergotamine nasal spray during migraine attacks. A double-blind crossover study with placebo. Cephalalgia. 1987;7:131-3. [PMID: 3301001]
46. Ziegler D, Ford R, Kriegler J, Gallagher RM, Peroutka S, Hammerstad J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology. 1994;44:447-53. [PMID: 8145914]
47. Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache. 1986;26:168-71. [PMID: 3519528]
48. Klapper J, Stanton J. The emergency treatment of acute migraine headache; a comparison of intravenous dihydroergotamine, dexamethasone, and placebo. Cephalalgia. 1991;11(Suppl 11):159-60.
49. Hoffert MJ, Couch JR, Diamond S, Elkind AH, Goldstein J, Kohlerman NJ 3rd, et al. Transnasal butorphanol in the treatment of acute migraine. Headache. 1995;35:65-9. [PMID: 7737863]
50. Goldstein J, Gawel MJ, Winner P, et al. Comparison of butorphanol nasal spray and fiorinal with codeine in the treatment of migraine. Headache. 1998;38:516-22.
51. Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med. 1995;26:541-6. [PMID: 7486359]
52. Ellis GL, Delaney J, DeHart DA, Owens A. The efficacy of metoclopramide in the treatment of migraine headache. Ann Emerg Med. 1993;22:191-5. [PMID: 8427430]
53. Tek DS, McClellan DS, Olshaker JS, Allen CL, Arthur DC. A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department. Ann Emerg Med. 1990;19:1083-7. [PMID: 2221512]
54. Diamond S, Medina JL. Isometheptene - A non-ergot drug in the treatment of migraine. Headache. 1975;15:211-3. [PMID: 1100566]
55. Ryan RE. A study of midrin in the symptomatic relief of migraine headache. Headache. 1974;14:33-42. [PMID: 4599014]
56. Matchar DB, McCrory DC, Gray RN. Toward evidence-based management of migraine [Editorial]. JAMA. 2000;284:2640-1. [PMID: 11086374]
57. Borgesen SE, Nielsen JL, Moller CE. Prophylactic treatment of migraine with propranolol. A clinical trial. Acta Neurol Scand. 1974;50:651-6. [PMID: 4611129]
58. Forssman B, Henriksson KG, Johannsson V, Lindvall L, Lundin H. Propranolol for migraine prophylaxis. Headache. 1976;16:238-45. [PMID: 977330]
59. Johnson RH, Hornabrook RW, Lambie DG. Comparison of mefenamic acid and propranolol with placebo in migraine prophylaxis. Acta Neurol Scand. 1986;73:490-2. [PMID: 3524092]
60. Mikkelsen B, Pedersen KK, Christiansen LV. Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo. Acta Neurol Scand. 1986;73:423-7. [PMID: 3727918]
61. Pradalier A, Serratrice G, Collard M, Hirsch E, Feve J, Masson M, et al. Long-acting propranolol in migraine prophylaxis: Results of a double-blind, placebo-controlled study. Cephalalgia. 1989;9:247-53. [PMID: 2692838]
62. Sargent J, Solbach P, Damasio H, Baumel B, Corbett J, Eisner L, et al. A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache. 1985;25:320-4. [PMID: 3902723]
63. Tfelt-Hansen P, Standnes B, Kangasneimi P, Hakkarainen H, Olesen J. Timolol vs propranolol vs placebo in common migraine prophylaxis: A double-blind multicenter trial. Acta Neurol Scand. 1984;69:1-8. [PMID: 6367336]
64. Briggs RS, Millac PA. Timolol in migraine prophylaxis. Headache. 1979;19:379-81. [PMID: 511540]
65. Stellar S, Ahrens SP, Meibohm AR, Reines SA. Migraine prevention with timolol. A double-blind crossover study. JAMA. 1984;252:2576-80. [PMID: 6387197]
66. Mathew NT. Prophylaxis of migraine and mixed headache. A randomized controlled study. Headache. 1981;21:105-9. [PMID: 7021472]
67. Forssman B, Lindblad CJ, Zbornikova V. Atenolol for migraine prophylaxis. Headache. 1983;23:188-90. [PMID: 6350226]
68. Johannsson V, Nilsson LR, Widelius T, Jäverfalk T, Hellman P, Akesson JA, et al. Atenolol in migraine prophylaxis a double-blind cross-over multicentre study. Headache. 1987;27:372-4. [PMID: 3308768]
69. Andersson PG, Dahl S, Hansen JH, Hansen PE, Hedman C, Kristensen TN, et al. Prophylactic treatment of classical and non-classical migraine with metoprolol - A comparison with placebo. Cephalalgia. 1983;3:207-12. [PMID: 6640652]
70. Kangasniemi P, Andersen AR, Andersson PG, Gilhus NE, Hedman C, Hultgren M, et al. Classic migraine: Effective prophylaxis with metoprolol. Cephalalgia. 1987;7:231-8. [PMID: 3322569]
71. Steiner TJ, Joseph R, Hedman C, Rose FC. Metoprolol in the prophylaxis of migraine: Parallel-groups comparison with placebo and dose-ranging follow-up. Headache. 1988;28:15-23. [PMID: 3277926]
72. Freitag FG, Diamond S. Nadolol and placebo comparison study in the prophylactic treatment of migraine. J Am Osteopath Assoc. 1984;84:343-7. [PMID: 6150909]
73. Ryan RE Sr, Ryan RE Jr, Sudilovsky A. Nadolol: Its use in the prophylactic treatment of migraine. Headache. 1983;23:26-31. [PMID: 6131052]
74. Sudilovsky A, Stern MA, Mayer JH. Naldolol: The benefits of an adequate trial duration in the prophylaxis of migraine. Headache. 1986;26:325.
75. Couch JR, Hassanein RS. Migraine and depression: Effect of amitriptyline prophylaxis. Trans Am Neurol Assoc. 1976;101:234-7.
76. Couch JR, Hassanein RS. Amtriptyline in migraine prophylaxis. Arch Neurol. 1979;36:695-9.
77. Gomersall JD, Stuart A. Amitripryline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychiatry. 1973;36:684-90. [PMID: 4731336]
78. Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. Headache. 1992;32:101-4. [PMID: 1551787]
79. Steiner TJ, Ahmed F, Findley LJ, MacGregor EA, Wilkinson M. S-fluoxetine in the prophylaxis of migraine: A phase II double-blind randomized placebo-controlled study. Cephalalgia. 1998;18:283-6. [PMID: 9673809]
80. Klapper JA. An open-label cross-over comparison of divalproex sodium and propranolol HCl in the prevention of migraine headaches. Headache Quarterly. 1994;5:50-3.
81. Klapper J. Divalproex sodium in migraine prophylaxis: A dose-controlled study. Cephalalgia. 1997;17:103-8. [PMID: 9137847]
82. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995;52:281-6. [PMID: 7872882]
83. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: A double-blind study versus placebo. Cephalalgia. 1992;12:81-4. [PMID: 1576648]
84. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: A triple-blind, placebo-controlled crossover study. Neurology. 1994;44:647-51. [PMID: 8164818]
85. Mathew N, Saper J, Magnus-Miller L. Efficacy and safety of gabapentin (Neurontin) in migraine prophylaxis [Abstract]. San Diego, CA: 17th Annual Meeting of the American Pain Society; 5-8 November 1998. Abstract no. 645.
86. Drug Treatments for the Prevention of Migraine Headache. Technical Review 2.3. February 1999. Prepared for the Agency for Healthcare Policy and Research (contract no. 290-94-2025). Available from the National Technical Information Service (NTIS Accession No. 127953.
87. Bellavance AJ, Meloche JP. A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. Headache. 1990;30:710-5. [PMID: 2074163]
88. Lindegaard KF, Ovrelid L, Sjaastad O. Naproxen in the prevention of migraine attacks. A double-blind placebo-controlled cross-over study. Headache. 1980;20:96-8. [PMID: 6989789]
89. Sances G, Martignoni E, Fioroni L, Blandini F, Facchinetti F, Nappi G. Naproxen sodium in menstrual migraine prophylaxis: A double-blind placebo controlled study. Headache. 1990;30:705-9. [PMID: 2074162]
90. Szekely B, Merryman S, Croft H, Post G. Prophylactic effects of naproxen sodium on perimenstrual headache: A double-blind, placebo-controlled study. Cephalalgia. 1989;9(Suppl 10):452-3.
91. Welch KM, Ellis DJ, Keenan PA. Successful migraine prophylaxis with naproxen sodium. Neurology. 1985;35:1304-10. [PMID: 4022376]
92. Ziegler DK, Ellis DJ. Naproxen in prophylaxis of migraine. Arch Neurol. 1985;42:582-4. [PMID: 4004602]
93. Autret A, De Chasteigner C. DHE methane sulfonate with programmed liberation: Preliminary results of a controlled study in common migraine. Cephalalgia. 1987;7(Suppl 6):451-2.
94. Martucci N, Manna V, Mattesi P, Troiani G, Manzoni GC, Lanfranchi M, et al. Ergot derivatives in the prophylaxis of migraine: A multicentric study with a timed-release dihydroergotamine formulation. Cephalalgia. 1983;3 Suppl 1:151-5. [PMID: 6352046]
95. Neuman M, Demarez JP, Harmey JL, Le Bastard B, Cauquil J. Prevention of migraine attacks through the use of dihydroergotamine. Int J Clin Pharmacol Res. 1986;6:11-3. [PMID: 3514491]
96. Bousser MG, Chick J, Fuseau E, Soisson T, Thevenet R. Combined low-dose acetylsalicylic acid and dihydroergotamine in migraine prophylaxis. A double-blind, placebo-controlled crossover study. Cephalalgia. 1988;8:187-92. [PMID: 3197098]
97. Lance JW, Fine RD, Curran DA. An evaluation of methysergide in the prevention of migraine and other vascular headaches. Med J Aust. 1963;(Jun): 814-8.
98. Pedersen E, Moller CE. Methysergide in migraine prophylaxis. Clin Pharmacol Ther. 1966;7:520-6. [PMID: 5328472]
99. Ryan RE. Double-blind crossover comparison of bc-105, methysergide and placebo in the prophylaxis of migraine headache. Headache. 1968;8:118-26. [PMID: 4892617]
100. Shekelle RB, Ostfeld AM. Methysergide in the migraine syndrome. Clin Pharmacol Ther. 1964;5:201-4.
101. Herrmann WM, Kristof M, Sastre M, Sastre M. Preventive treatment of migraine headache with a new isoergolenyl derivative. J Int Med Res. 1978;6:476-82. [PMID: 363486]
102. Sances G, Martignioni E, Rosettino G, et al. Lisuride in menstrual migraine prophylaxis. Cephalalgia. 1989;9(Suppl 10):444-55.
103. Somerville BW, Herrmann WM. Migraine prophylaxis with Lisuride hydrogen maleate - A double blind study of Lisuride versus placebo. Headache. 1978;18:75-9. [PMID: 348647]
104. Zuddas A. Usefulness of lisuride on menstrual migraine in a double-blind trial. Cephalalgia. 1985;5(Suppl 3):514-5.
105. Arthur GP, Hornabrook RW. The treatment of migraine with BC 105 (pizotifen): A double blind trial. N Z Med J. 1971;73:5-9. [PMID: 4925988]
106. Carroll JD, Maclay WP. Pizotifen (BC 105) in migraine prophylaxis. Curr Med Res Opin. 1975;3:68-71. [PMID: 1095308]
107. Krakowski AJ, Engisch R. A new agent for chemotherapy of migraine headaches: A controlled study. Psychosomatics. 1973;14:302-8. [PMID: 4604015]
108. Lawrence ER, Hossain M, Littlestone W. Sanomigran for migraine prophylaxis, controlled multicenter trial in general practice. Headache. 1977;17:109-12. [PMID: 330465]
109. Osterman PO. A comparison between placebo, pizotifen and 1-isopropyl-3-hydroxy-5-semicarbazono-6-oxo-2.3.5.6-tetrahydroindol (Divascan) in migraine prophylaxis. Acta Neurol Scand. 1977;56:17-28. [PMID: 327746]
110. Ryan RE. BC-105 a new preparation for the interval treatment of migraine - A double blind evaluation compared with a placebo. Headache. 1971;11:6-18. [PMID: 5554982]
111. al Deeb SM, Biary N, Bahou Y, al Jaberi M, Khoja W. Flunarizine in migraine: A double-blind placebo-controlled study (in a Saudi population). Headache. 1992;32:461-2. [PMID: 1446992]
112. Diamond S, Freitag FG. A double-blind trial of flunarizine in migraine prophylaxis. Headache Quarterly. 1993;4:169-72.
113. Louis P. A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine. Headache. 1981;21:235-9. [PMID: 7031016]
114. Sørensen PS, Hansen K, Olesen J. A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia. 1986;6:7-14. [PMID: 3516409]
115. Frenken CW, Nuijten ST. Flunarizine, a new preventive approach to migraine. A double-blind comparison with placebo. Clin Neurol Neurosurg. 1984; 86:17-20. [PMID: 6325065]
116. Adam EI, Gore SM, Price WH. Double-blind trial of clonidine in the treatment of migraine in general practice. J Coll Gen Pract. 1978;28:587-90.
117. Das SM, Ahuja GK, Narainaswamy AS. Clonidine in prophylaxis of migraine. Acta Neurol Scand. 1979;60:214-7. [PMID: 393047]
118. Mondrup K, Moller CE. Prophylactic treatment of migraine with clonidine. A controlled clinical trial. Acta Neurol Scand. 1977;56:405-12. [PMID: 339659]
119. Ryan RE Sr, Diamond S, Ryan RE Jr. Double blind study of clonidine and placebo for the prophylactic treatment of migraine. Headache. 1975;15:202-10. [PMID: 1100565]
120. Shafar J, Tallett ER, Knowlson PA. Evaluation of clonidine in prophylaxis of migraine. Double-blind trial and follow-up. Lancet. 1972;1:403-7. [PMID: 4110641]
121. Elkind AH, Webster C, Herbertson RK. Efficacy of guafacine in a double-blind parallel study for migraine prophylaxis. Cephalalgia. 1989;9(Suppl 10):369-70.